Robert Olson, MD, on Quality-of-Life Outcomes After Stereotactic Ablative Radiotherapy vs Standard-of-Care Palliative Treatments
2019 ASTRO Annual MeetingRobert Olson, MD, of the BC Cancer Centre for the North, discusses a secondary analysis of the SABR-COMET trial, which showed there was a small magnitude decline in quality of life in both arms of the study but no associated detriment with stereotactic ablative radiotherapy (Abstract 148).
Related Videos
Steven H. Lin, MD, PhD, on Esophageal Cancer: Proton Beam vs Intensity-Modulated Radiation Therapy
Steven H. Lin, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses phase II findings that showed proton beam therapy improved total toxicity burden score...
Andrew Kneebone, MD, on an ANZUP Trial on Adjuvant vs Early Salvage Radiotherapy After Prostatectomy
Andrew Kneebone, MD, of Royal North Shore Hospital, discusses phase III study findings showing that at 5 years, biochemical control was similar between adjuvant and early sal...
Ryan Phillips, MD, PhD, on Oligometastatic Prostate Cancer: ORIOLE Trial on Observation vs Stereotactic Ablative Radiation
Ryan Phillips, MD, PhD, of Johns Hopkins Medical Institutions, discusses phase II findings suggesting that treatment with stereotactic ablative radiation significantly decrea...
David Routman, MD, on Oropharyngeal Squamous Cell Carcinoma and HPV Circulating Tumor DNA
David Routman, MD, of the Mayo Clinic, discusses his study findings showing that detectable human papillomavirus circulating tumor DNA in the postoperative setting may be lin...
Erica H. Bell, PhD, on Low-Grade Gliomas: Subgroup Analysis of the NRG Oncology/RTOG 9802 Trial
Erica H. Bell, PhD, of The Ohio State University, discusses phase III findings from a prognostic and predictive molecular subgroup analysis of radiotherapy vs radiotherapy pl...
